Malignant tumors of skin take the leading place in neoplastic incidence worldwide. Currently, concerning the development of molecular biology and genetics, it becomes clear that these tumors are heterogenic and have different biological characteristics that of prognostic and predictive significance. Various degree of integrin receptors expression, which can influence processes of an invasion and metastasis, belongs to such changes. We review the problem of modern understanding of the integrin’s influence on skin tumor progression and development of new approaches for antineoplastic therapy application.

Male breast cancer (MBC), is very rare disease in spite of the women’s. That is why it has not been thoroughly investigated in terms of transcriptional profiles or genomic aberrations.. Most of our understanding of MBC has therefore been extrapolated from knowledge of female breast cancer. The same prognostic and predictive markers are used to determine optimal management strategies for both men and women diagnosed with breast cancer. This article is focused on prognosis for MBC patients, prognostic and predictive factors and molecular subgrouping. Information was collected from 2000 till 2014 y. about 84 men with the breast cancer. We could not found the HER2-neu biological type of the tumour and combine all patients for two groups: Luminal A and Non luminal A. All patients were treated by chemotherapy, hormonotherapy or combination chemohormonotherapy. No advantages were found in the Luminal A subtype between hormonotherapy and combination chemohormonotherapy but in the Nonluminal A subtype 5 y. overall survival were better when the patients were treated by combination of chemotherapy and hormonotherapy.

Paget’s cancer- is intraduct epidermotropny breast cancer that occurs in the mouth of the excretory ducts of the nipple. From 0.5 to 5% of all cases of breast neoplasia. According to the literature in the description of Paget’s breast cancer usually refers to the primary lesion of the nipple and areola, much rarer describes nodular lesions without nipple-areola complex.

Today the colorectal cancer still one of the most common oncological disease in the World. Every Year diagnosed more then 1,4 mln new cases of colorectal cancer. Approximately 40% of them – able-bodied citizens. Nowadays we achieved good results in colorectal cancer treatment thanks to multidisciplinary treatment scheme. Actual problem is to preserve quality of life, especially after neoadjuvant chemoradiotherapy. A good known that after low rectal resection patient have a high risk of low anterior resection syndrome – LARS (fecal incontinence, diarrhea, tenesmus etc). The main factor for LARS – loss of reservoir function of the rectum, the most promising direction was the work on the formation of reservoir from the remaining intestine.

Moscow developmental program results on assessment of luteinizing hormone-releasing hormone (gonadotrophinreleasing hormone) antagonist degarelix efficacy and tolerance in patients with prostate cancer received drug treatment in specialized outpatient polyclinic institutions of Moscow are provided in the original publication. In total 307 patients were included in the study and assigned in 3 groups: 1st (n=174) – patients with progressing prostate cancer after radical treatment (prostatectomy, radiation therapy); 2d (n=92) – patients with prostate cancer had cardiovascular diseases in history; 3d (n=41) – patients with prostate cancer with early castration refractivity occurred on the background of continuous hormone therapy by luteinizing hormone-releasing hormone antagonists. In all groups degarelix was prescribed in standard therapeutic regimen (240 mg/80 mg). Degarelix was effective in all test groups that was manifested by PSA level decrease on the background of one-year drug treatment, high control of testosterone castration level. Treatment by degarelix allowed increasing time before chemotherapy prescription (up to 12 months) in certain group of patients with biochemical progression on the background of luteinizing hormone-releasing hormone analogues administration. Degarelix tolerance was good even in patients with clinically significant cardiovascular pathology in history. In 4% of cases significant reactions were observed in the injection site after start dose administration.

The aim of the present study is the analysis of the results of the reconstruction of oncologic defects of the oral cavity with the infrahyoid musculocutaneous flap. Materials and methods Since July, 2009 through February, 2016 41 patients with oral cavity cancer (floor of the mouth – 33, tongue – 4, lower gingiva – 3 and retromolar trigone – 1) aged between 45 and 73 year were operated on. 11 patients had T1, 18 – T2, 1 – T3 and 11 – T4 tumors. 17 patients were N positive. Marginal and segmental mandibulectomy was performed in 19 and 1 cases, respectively. Neck dissection was performed in 39 patients being bilateral in 16 cases. Quality of life (QoL) assessment was performed with standard EORTC QLQ-C30 version 3.0 EORTC QLQ-H&N35 questionnaires before and 6 to 9 months after the completion of the treatment. Results Partial flap loss was observed in 10 cases (24%). Muscular portion of the flap remained viable in all cases. Relatively low incidence of the salivary fistula (2,4%) can be explained by that fact. Neck wound breakdown occurred in 9 patients (22%). All patients were able to resume oral food intake 8,3 days after the operation on average. All complications were managed conservatively. QoL assessment revealed significant improvement in pain and function scale. Conclusions Infrahyoid musculocutaneous flap is one of the safe and reliable option for the reconstruction of the oral cavity defects.

Today, we must concede that our country remains relatively isolated from the international medical community, and the quantitative contribution, ie the number of articles published in international medical publications disproportionately small, in spite of the considerable clinical and scientific experience. It is therefore important to know how to properly present the results of their research in the medical article. The structure is one of the essential components of such articles. In this paper, the author tries to highlight the issues of building of a medical article.